Phase 3 clinical trials indicate that people lost 28.3% of their body weight after 80 weeks on 12 mg of retatrutide, with 45% losing 30% or more of their weight
S., McGill, J
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
Developed exclusively for laboratory research, this multi-peptide formulation is designed to support scientific investigations involving cellular signaling, tissue-response mechanisms, extracellular matrix dynamics, and peptide interactions
Jassim HN, Aziz SB, Hussein SA, Brza MA
Digestive issues like diarrhea, constipation, or abdominal discomfort